AbbVie to Acquire Allergan
AbbVie Inc. and Allergan plc have announced that they have entered into a definitive transaction agreement under which AbbVie will acquire Allergan for approximately $63 billion. The combined company will consist of several franchises with focus across immunology, hematologic oncology, medical aesthetics, neuroscience, women's health, eye care, and virology.
Learn all about the acquisition, right here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
